Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers
This study has been completed.
Sponsor:
Remedy Pharmaceuticals, Inc.
Information provided by:
Remedy Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01132703
First received: April 14, 2010
Last updated: May 26, 2010
Last verified: May 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is to evaluate the safety and tolerability of RP-1127 (glyburide for injection), administered as a bolus dose followed by a 3 day continuous infusion. The secondary objectives are to assess the pharmacokinetics of RP-1127 and blood glucose and serum insulin PD responses to RP-1127.
| Condition | Intervention | Phase |
|---|---|---|
|
Traumatic Brain Injury Stroke |
Drug: RP-1127 (Glyburide for injection) Drug: Placebo (RP-1127 excipients, excluding active) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of RP-1127 (Glyburide for Injection) in Healthy Male and Female Volunteers |
Resource links provided by NLM:
Further study details as provided by Remedy Pharmaceuticals, Inc.:
Primary Outcome Measures:
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 28 Days ] [ Designated as safety issue: Yes ]In particular, events of hypoglycemia and EKG changes will be studied
| Estimated Enrollment: | 30 |
| Study Start Date: | February 2010 |
| Study Completion Date: | May 2010 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: RP-1127 (Glyburide for Injection) |
Drug: RP-1127 (Glyburide for injection)
RP-1127 is administered as a bolus followed by continuous infusion for 72 hours
|
|
Placebo Comparator: Placebo
Placebo (RP-1127 excipients without active)
|
Drug: Placebo (RP-1127 excipients, excluding active)
RP-1127 excipients, excluding active
|
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Between 18 and 55 years of age, inclusive.
- A healthy male or a healthy nonpregnant, nonlactating female.
- Capable of understanding and complying with the protocol and has signed the informed consent form before the Screening procedures begin.
- Have a body mass index of between 18.0 and 30.0 kg/m², inclusive.
- A clinically normal physical examination, 12-lead electrocardiogram (ECG), screening laboratory studies and urinalysis.
- A negative urine or saliva test for selected substances of abuse and cotinine.
Exclusion Criteria:
- Clinically significant history of hypoglycemia as assessed by the investigator.
- History of seizure disorder, even if currently not receiving anticonvulsant medications.
- History of adverse reaction to glyburide, other sulfonylurea class of anti-diabetic medications, or other sulfa drugs.
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency as determined by G6PD enzyme testing at screening.
- Be an active smoker or user of other forms of tobacco. Former smokers or tobacco users must have refrained from smoking or using other forms of tobacco for at least 6 months prior to dosing on Study Day 1.
- A history or clinical manifestations of significant metabolic (including diabetes mellitus, hypercholesterolemia, or dyslipidemia), hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, immunologic, or psychiatric disorders (a history of mild depression, currently not receiving therapy, is acceptable).
- Use any prescription medication within 14 days prior to randomization, or nonprescription drugs within 7 days. Exceptions may be made by the medical monitor on a case-by-case basis.
- Received another investigational drug within 30 days prior to randomization.
- A positive hepatitis virus test (Hepatitis B virus surface antigen or hepatitis C virus antibody) or a positive human immunodeficiency virus (HIV) antibody test at screening. If the HIV test is positive, the subject will be informed privately and referred for additional counseling.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | CEO, Remedy Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT01132703 History of Changes |
| Other Study ID Numbers: | RPI 101 |
| Study First Received: | April 14, 2010 |
| Last Updated: | May 26, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Stroke Brain Injuries Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases |
Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries Glyburide Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013